Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-07-19
2005-07-19
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S269000, C544S298000, C544S327000, C544S328000
Reexamination Certificate
active
06919345
ABSTRACT:
This invention relates to pyrazol pyridine derivatives of formula (I)wherein R1is a radical of the formula −O—SO2—R3in which R3is optionally substituted C1—6—alkyl, optionally substituted C3—8—cycloalkyl, or optionally substituted phenyl; R2is H, optionally substituted C1—6—alkyl —CO—or optionally substituted C1—6—alkyl—SO2— ; as well as salts, stereoisomers, tautomers, and hydrates thereof. Pharmaceutical compositions containing these materials and methods of using them in medical treatment are also described and claimed.
REFERENCES:
patent: 6180656 (2001-01-01), Furstner et al.
patent: 6451805 (2002-09-01), Straub et al.
patent: 6462068 (2002-10-01), Straub et al.
patent: 6743798 (2004-06-01), Straub et al.
patent: 19834045 (2000-02-01), None
patent: 19834047 (2000-02-01), None
patent: 10057751 (2002-05-01), None
patent: 9816223 (1998-04-01), None
patent: 9816507 (1998-04-01), None
patent: 9823619 (1998-06-01), None
patent: 0006567 (2000-02-01), None
patent: 0006568 (2000-02-01), None
patent: 0006569 (2000-02-01), None
patent: 0021954 (2000-04-01), None
Prandoni, The treatment of venous thromboembolic disorders: new challenges and opportunities, Journal of Hematology, vol. 88(05):610-613, May 2003.
Wolin et al., Oxidant-Nitric Oxide Signalling Mechanisms in Vascular Tissue, Biochemistry (Moscow), vol. 63, No. 7, 810/958, 1998.
Layzer, Degenerative Diseases of the Nervous System, Cecil Textbook of Medicine, 20thEdition, vol. 2, pp. 2050-2057, 1996.
Damasio, Alzheimer's Disease and Related Dementias, Cecil Textbook of Medicine, 20thEdition, vol. 2, pp. 1992-1996, 1996.
Fisker, PubMed Abstract (J. Endocrinol. Invest. 22(5 Suppl):89-93, 1999.
Ko et al., YC-1, a Novel Activator of Platelet Guanylate Cyclase, Blood, 84, 4226-4233 (1994).
Mulsch, et al., Effect of YC-1, an NO-independent, Superoxide-Sensitive Stimulator of Soluble Guanylyl Cyclase, on Smooth Muscle Responsiveness to Nitrovasodilators, Brit. J. Pharm. 120, 681-689 (1997).
Glass et al., Stimulation of Human Platelet Guanylate Cyclase by Fatty Acids, J. Biol. Chem., 252, 1279-1285 (1977).
Pettibone et al., A Structurally Novel Stimulator of Guanylate Cyclase with Long-lasting Hypotensive Activity in the Dog, European J. Pharm. 116, 307-312 (1985).
Yu et al., Vasorelaxant Effect of Isoliquiritigenin, a Novel Soluble Guanylate Cyclase Activator , in Rat Aorta, Brit. J. Pharm. 114, 1587-1594 (1995).
Alonso-Alija Cristina
Dembowsky Klaus
Feurer Achim
Flubacher Dietmar
Lang Dieter
Bayer Aktiengesellschaft
Rao Deepak
LandOfFree
Sulfonate substituted pyrazol pyridine derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sulfonate substituted pyrazol pyridine derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sulfonate substituted pyrazol pyridine derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3389283